Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

FDA Alerts

Face
FDA Alerts
Bimekizumab FDA Approved for Moderate-to-Severe Hidradenitis Suppurativa
11/20/2024
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).
The US Food and Drug...
11/20/2024
The Dermatologist
PsA
FDA Alerts
Bimekizumab FDA Approved for the Treatment of Psoriatic Arthritis
09/24/2024
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
The US Food and Drug...
09/24/2024
The Dermatologist
atopic dermatitis
FDA Alerts
Lebrikizumab FDA Approved for Moderate to Severe Atopic Dermatitis in Adults and Children
09/16/2024
The US Food and Drug Administration has approved Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and children.
The US Food and Drug Administration has approved Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and children.
The US Food and Drug...
09/16/2024
The Dermatologist
Alopecia Areata, blad head
FDA Alerts
Deuruxolitinib FDA Approved for Severe Alopecia Areata in Adults
07/30/2024
The FDA has approved deuruxolitinib (LEQSELVI) 8 mg tablets for the treatment of adults with severe alopecia areata, a condition affecting approximately 300,000 individuals in the United States.
The FDA has approved deuruxolitinib (LEQSELVI) 8 mg tablets for the treatment of adults with severe alopecia areata, a condition affecting approximately 300,000 individuals in the United States.
The FDA has approved...
07/30/2024
The Dermatologist
Atopic dermatitis
FDA Alerts
FDA Approves Roflumilast Cream 0.15% for Treatment of Atopic Dermatitis in Adults and Children Aged 6 and Older
07/09/2024
The US Food and Drug Administration has approved roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children aged 6 and older.
The US Food and Drug Administration has approved roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children aged 6 and older.
The US Food and Drug...
07/09/2024
The Dermatologist
AD
FDA Alerts
FDA Approves Tralokinumab Autoinjector for Adults with Moderate-to-Severe Atopic Dermatitis
06/15/2024
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug...
06/15/2024
The Dermatologist
Actinic Keratosis
FDA Alerts
FDA Approves Almirall’s Klisyri for Expanded Treatment Area of Actinic Keratosis
06/11/2024
The US Food and Drug Administration (FDA) has recently approved an expansion for the use of Klisyri (tirbanibulin) to treat actinic keratosis (AK) on larger areas of the face or scalp, up to 100 cm².
The US Food and Drug Administration (FDA) has recently approved an expansion for the use of Klisyri (tirbanibulin) to treat actinic keratosis (AK) on larger areas of the face or scalp, up to 100 cm².
The US Food and Drug...
06/11/2024
The Dermatologist
Atopic Derm
FDA Alerts
Dupixent Receives Expanded FDA Approval for Atopic Dermatitis with Moderate to Severe Hand and Foot Involvement
01/19/2024
The US FDA has approved an update to the label for Dupixent (dupilumab) for atopic dermatitis for patients ages 12 years and older with AD and uncontrolled moderate to severe involvement of the hands and/or feet.
The US FDA has approved an update to the label for Dupixent (dupilumab) for atopic dermatitis for patients ages 12 years and older with AD and uncontrolled moderate to severe involvement of the hands and/or feet.
The US FDA has approved an...
01/19/2024
The Dermatologist
atopic dermatitis
FDA Alerts
Tralokinumab-ldrm Approved for Treatment of Moderate to Severe Atopic Dermatitis in Pediatric Patients
12/18/2023
The US Food and Drug Administration recently announced approval of tralokinumab-ldrm (Adbry) to include pediatric patients aged 12 to 17 years with moderate to severe atopic dermatitis.
The US Food and Drug Administration recently announced approval of tralokinumab-ldrm (Adbry) to include pediatric patients aged 12 to 17 years with moderate to severe atopic dermatitis.
The US Food and Drug...
12/18/2023
The Dermatologist
Roflumilast Topical Foam
FDA Alerts
Roflumilast Topical Foam, 0.3% Approved for Treatment of Seborrheic Dermatitis
12/18/2023
As the first drug approved for seborrheic dermatitis with a new mechanism of action in over 2 decades, roflumilast foam, 0.3% is indicated for treatment of seborrheic dermatitis in adult and pediatric patients.
As the first drug approved for seborrheic dermatitis with a new mechanism of action in over 2 decades, roflumilast foam, 0.3% is indicated for treatment of seborrheic dermatitis in adult and pediatric patients.
As the first drug approved for...
12/18/2023
The Dermatologist

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Current Issue

October 2024
Volume 32
Issue 7
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Popular Articles

AGELESS Face Visualizer App Review
02/12/2017
Spencer D Hawkins, and Sarah Taylor, MD, MPH
This personalized 3-D treatment visualizer app simulates aging of facial skin, explores how various aesthetic options might affect appearance, and provides patient education.
This personalized 3-D treatment visualizer app simulates aging of facial skin, explores how various aesthetic options might affect appearance, and provides patient education.
This personalized 3-D treatment...
02/12/2017
The Dermatologist
Deadline Extension for Meaningful Use 2013 Reporting
02/10/2014
To fulfill Stage 1 of meaningful use, dermatologists need to complete all 15 core measures listed below — unless an exclusion applies â€” and select five additional measures to complete from a set of 10 measures. All...
To fulfill Stage 1 of meaningful use, dermatologists need to complete all 15 core measures listed below — unless an exclusion applies â€” and select five additional measures to complete from a set of 10 measures. All...
To fulfill Stage 1 of meaningful...
02/10/2014
The Dermatologist
2016: Year In Review
12/30/2016
It has been an impressive year in the field of dermatology. This annual article highlights some of the advances, discoveries, and recommendations that have made 2016 a great year in dermatology.
It has been an impressive year in the field of dermatology. This annual article highlights some of the advances, discoveries, and recommendations that have made 2016 a great year in dermatology.
It has been an impressive year...
12/30/2016
The Dermatologist
MELA Sciences Appoints New President and Chief Executive
11/07/2013
MELA Sciences Inc. has appointed Rose Crane as its president and chief executive officer and a director, effective as of November 11, 2013. MELA Science markets MelaFind is the FDA approved automatic (algorithm-based) optical...
MELA Sciences Inc. has appointed Rose Crane as its president and chief executive officer and a director, effective as of November 11, 2013. MELA Science markets MelaFind is the FDA approved automatic (algorithm-based) optical...
MELA Sciences Inc. has appointed...
11/07/2013
The Dermatologist
What`s Causing This Woman`s Itchy, Painful, Fissured Fingers And Palms?
11/21/2016
Alexander K. C. Leung, MD, Benjamin Barankin, MD, FRCPC
In this case, a 34-year-old woman presented with mildly pruritic and somewhat painful hands of approximately 6 months’ duration.
In this case, a 34-year-old woman presented with mildly pruritic and somewhat painful hands of approximately 6 months’ duration.
In this case, a 34-year-old...
11/21/2016
The Dermatologist

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

The Dermatologist Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Latest Quizzes and Trivia

Atopic dermatitis
Quiz
Pediatric Atopic Dermatitis Management
11/11/2024
1. What alternative therapies does Dr Swanson suggest for children who have difficulty adhering to topical treatment regimens?a) Antibioticsb) Injectable or oral medicationsc) UV light therapyd) Homeopathic remedies2. According to Dr Swanson,...
1. What alternative therapies does Dr Swanson suggest for children who have difficulty adhering to topical treatment regimens?a) Antibioticsb) Injectable or oral medicationsc) UV light therapyd) Homeopathic remedies2. According to Dr Swanson,...
1. What alternative therapies...
11/11/2024
The Dermatologist
Illustration of a T cell
QUIZ
Test Your Knowledge: The Immunology of Alopecia Areata
11/04/2024
11/04/2024
The Dermatologist
psoriasis
Quiz
Long-Term Safety of Risankizumab
10/18/2024
What were the primary findings regarding the long-term safety of risankizumab?
What were the primary findings regarding the long-term safety of risankizumab?
What were the primary findings...
10/18/2024
The Dermatologist
Brain
Quiz
Barriers to Mental Health Support
10/10/2024
What was the first barrier to mental health support for patients with atopic dermatitis identified in the NEA survey?
What was the first barrier to mental health support for patients with atopic dermatitis identified in the NEA survey?
What was the first barrier to...
10/10/2024
The Dermatologist
AD
Quiz
QUIZ: Psoriasis and Atopic Dermatitis: Nonsteroidal Topical Therapies
09/15/2024
1. According to Dr Linda Stein Gold, how do nonsteroidal topical therapies compare to traditional steroid-based treatments for managing psoriasis and AD?a) They are less effective but safer.b) They are as effective as mid-potency steroids and...
1. According to Dr Linda Stein Gold, how do nonsteroidal topical therapies compare to traditional steroid-based treatments for managing psoriasis and AD?a) They are less effective but safer.b) They are as effective as mid-potency steroids and...
1. According to Dr Linda Stein...
09/15/2024
The Dermatologist
psoriasis
Quiz
QUIZ: Topical PDE-4 Inhibitors For Atopic Dermatitis, Seborrheic Dermatitis, and Psoriasis
08/10/2024
What strategies did Dr Merola emphasize for atopic dermatitis?
What strategies did Dr Merola emphasize for atopic dermatitis?
What strategies did Dr Merola...
08/10/2024
The Dermatologist
contact dermtitis + Neck + Eczema + rash
Quiz
QUIZ: Patient Experiences in Contact Dermatitis and Patch Testing
07/14/2024
What is a common challenge for patients during the patch testing week?
What is a common challenge for patients during the patch testing week?
What is a common challenge for...
07/14/2024
The Dermatologist
gloves hands
Quiz
Quiz: Barrier to Mental Health Support in Patients with Atopic Dermatitis
05/30/2024
According to a recent interview with Jessica Johnson, MPH, what is a significant barrier to seeking mental health support among patients with atopic dermatitis?
According to a recent interview with Jessica Johnson, MPH, what is a significant barrier to seeking mental health support among patients with atopic dermatitis?
According to a recent interview...
05/30/2024
The Dermatologist
Atopic dermatitis
Quiz
Quiz: Atopic Dermatitis Spotlight
05/06/2024
Which class of medications received a "general thumbs up" in the latest guidelines for atopic dermatitis management due to their efficacy and low cancer risk?
Which class of medications received a "general thumbs up" in the latest guidelines for atopic dermatitis management due to their efficacy and low cancer risk?
Which class of medications...
05/06/2024
The Dermatologist
basal cell carcinoma
Quiz
True or False: Basal Cell Carcinoma on Vermilion Lip
05/01/2024
Is basal cell carcinoma on the vermilion lip a distinctly rare phenomenon, sparsely documented in existing literature?
Is basal cell carcinoma on the vermilion lip a distinctly rare phenomenon, sparsely documented in existing literature?
Is basal cell carcinoma on the...
05/01/2024
The Dermatologist

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement